Efficacy of TPI ASM8 During a 14-Day Allergen Challenge
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, 3-way crossover trial to evaluate the
efficacy and safety of two different doses of inhaled TPI ASM8 administered daily for 14 days
for the treatment of allergic asthma and allergen-induced asthma.